Therapeutic Response

BRCA1 pathogenic variants status confers therapeutic sensitivity to Olaparib in patients with Pancreatic Adenocarcinoma.

Statements

Source and description
Lynparza (olaparib) [product monograph]. HC. Health Canada approved olaparib as monotherapy for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic adenocarcinoma of the pancreas whose disease has not progressed on a minimum of 16 weeks of first-line platinum-based chemotherapy.
Lynparza (olaparib) [package insert]. FDA. The U.S. Food and Drug Administration granted approval to olaparib for the maintenance treatment of adult patients with deleterious or suspected deleterious gBRCAm metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Olaparib's product label specifies to select patients for therapy based on an FDA-approved companion diagnostic for Lynparza.